# Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/phase-3-efficacy-and-safety-of-abrocitinib-in-adults-with-moderate-to-severe/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Vivian Y. Shi,Tina Bhutani,Luz Fonacier,Mette Deleuran,Stephen Shumack,Hernán Valdez,Fan Zhang,Gary Chan,Michael C. Cameron,Natalie Yin |
| Citations | 97 |
| DOI | 10.1016/j.jaad.2022.04.009 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | http://www.jaad.org/article/S0190962222006089/pdf |
| OpenAlex ID | https://openalex.org/W4224060947 |
| PMID | 35439608 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Vivian Y. Shi](https://scholariq.org/researchers/vivian-y-shi/)

## Paper primary topic

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)

## Paper topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Drug-Induced Adverse Reactions](https://scholariq.org/topics/drug-induced-adverse-reactions/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.